S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:VAXX

Vaxxinity - VAXX Stock Forecast, Price & News

$3.58
+0.53 (+17.38%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.94
$3.62
50-Day Range
$1.31
$3.58
52-Week Range
$1.24
$8.35
Volume
542,347 shs
Average Volume
501,595 shs
Market Capitalization
$451.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Vaxxinity MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of Vaxxinity in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.16 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

1009th out of 1,055 stocks

Pharmaceutical Preparations Industry

492nd out of 519 stocks


VAXX stock logo

About Vaxxinity (NASDAQ:VAXX) Stock

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Stock News Headlines

Why Shares of Vaxxinity Jumped This Week
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Vaxxinity, Inc. (VAXX)
See More Headlines
Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Company Calendar

Last Earnings
11/10/2022
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VAXX
Fax
N/A
Employees
89
Year Founded
N/A

Profitability

Net Income
$-137,180,000.00
Pretax Margin
-603,670.63%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$1.03 per share

Miscellaneous

Free Float
44,889,000
Market Cap
$451.29 million
Optionable
Not Optionable
Beta
0.55

Key Executives

  • Mr. Louis Garfield Reese IV (Age 39)
    Co-Founder & Exec. Chairman
    Comp: $428.03k
  • Ms. Mei Mei Hu J.D. (Age 38)
    CEO & Director
    Comp: $428.03k
  • Dr. Ulo Palm M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $551.19k
  • Mr. Jason Pesile CPA (Age 49)
    M.B.A., Sr. VP of Fin. & Accounting
  • Mr. Dwayne Soisson
    VP of Operations
  • Mr. Benjamin Matone
    VP of Investor Relations
  • Mr. Rene Paula Molina (Age 43)
    Gen. Counsel & Sec.
  • Mr. Jon Harrison
    Chief Gov. Officer
  • Mr. Mark Joinnides
    Chief of Staff
  • Ms. Amy B. Fix M.B.A.
    M.S., R.A.C., Chief Regulatory Officer













VAXX Stock - Frequently Asked Questions

Should I buy or sell Vaxxinity stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VAXX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VAXX, but not buy additional shares or sell existing shares.
View VAXX analyst ratings
or view top-rated stocks.

How have VAXX shares performed in 2023?

Vaxxinity's stock was trading at $1.40 on January 1st, 2023. Since then, VAXX stock has increased by 155.7% and is now trading at $3.58.
View the best growth stocks for 2023 here
.

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our VAXX earnings forecast
.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01.

When did Vaxxinity IPO?

(VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share.

What is Vaxxinity's stock symbol?

Vaxxinity trades on the NASDAQ under the ticker symbol "VAXX."

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxxinity's stock price today?

One share of VAXX stock can currently be purchased for approximately $3.58.

How much money does Vaxxinity make?

Vaxxinity (NASDAQ:VAXX) has a market capitalization of $451.29 million and generates $70,000.00 in revenue each year. The company earns $-137,180,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How can I contact Vaxxinity?

The official website for the company is www.vaxxinity.com. The company can be reached via phone at 254-244-5739 or via email at ir@vaxxinity.com.

This page (NASDAQ:VAXX) was last updated on 1/28/2023 by MarketBeat.com Staff